Skip to main content

Table 2 Baseline subject demographic and clinical characteristics

From: Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study

Baseline characteristic Non-EU (n = 694) EU (n = 551) p-value
  Mean (SD) Mean (SD)  
Age (years) 68.0 (6.9) 67.5 (6.2) 0.1994
Height (cm) 159.7 (6.3) 160.1 (6.6) 0.3001
Weight (kg) 65.4 (11.0) 64.7 (9.9) 0.2467
Body mass index (kg/cm2) 25.7 (4.2) 25.2 (3.6) 0.0370*
Caucasian (n, %) 672 (96.8) 543 (98.5) 0.0619
Smoker (Yes) (n, %) 617 (88.9) 421 (76.4) <0.0001**
Use of alcohol (Yes) (n, %) 556 (80.1) 406 (73.7) 0.0038*
Number of prevalent vertebral fractures (≥1) (n, %) 433 (62.4) 279 (50.6) <0.0001**
Baseline femoral neck BMD (# of SDs < mean for females) −2.3 (.6) −2.2 (.6) 0.0022*
Number of osteoporotic non-vertebral fractures (≥1) (n, %) 366 (52.7) 202 (36.7) <0.0001**
Family history of osteoporosis (Yes) (n, %) 212 (30.5) 157 (28.5) 0.0001**
History of hysterectomy (Yes) (n, %) 186 (26.8) 134 (24.3) 0.3281
Married (Yes) (n, %) 390 (56.2) 314 (57.0) 0.7732
Number of years postmenopause 20.3 (8.7) 19.4 (7.7) 0.0551
Baseline lumbar spine BMD (# of SDs < mean for females) −2.4 (1.2) −2.7 (1.1) 0.0001**
Number of years of education 13.6 (3.1) 10.1 (3.2) <0.0001**
Number of self-reported preexisting conditions 10.9 (5.9) 5.9 (4.3) <0.0001**
  1. Abbreviations: BMD Bone mineral density, EU European Union, Non-EU Non-European Union, SD Standard deviation.
  2. *p < 0.05, **p < 0.0001.